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Abstract: Incidence of cardiovascular (CV) and metabolic disease is increasing, in parallel 
with associated risk factors. These factors, such as low-density lipoprotein (LDL)-cholesterol, 
elevated blood pressure, obesity, and insulin resistance have a continuous, progressive impact on 
total CV risk, with higher levels and numbers of factors translating into greater risk. Evaluation 
of all known modiﬁ  able risk factors, to provide a detailed total CV disease (CVD) and metabolic 
risk-status proﬁ  le is therefore necessary to ensure appropriate treatment of each factor within 
the context of a multifactorial, global approach to prevention of CVD and metabolic disease. 
Effective and well-tolerated pharmacotherapies are available for the treatment of risk-factors. 
Realization of the potential health and economic beneﬁ  ts of effective risk factor management 
requires improved risk factor screening, early and aggressive treatment, improved public health 
support (ie, education and guidelines), and appropriate therapeutic interventions based on cur-
rent guidelines and accurate risk assessment. Patient compliance and persistence to available 
therapies is also necessary for successful modulation of CVD risk.
Keywords: cardiovascular disease, risk factors, risk factor management, metabolic syndrome, 
blood pressure, obesity, hyperlipidemia, insulin resistance, new-onset diabetes, implementation
Introduction
Cardiovascular (CV) disease is the leading cause of disability and death in developed 
nations and is increasing in prevalence throughout the developing world (WHO 2002). 
It also poses a huge economic burden; for example, in Sweden in 2005, CV disease 
(CVD) cost an estimated 48 billion SEK (US$7 billion), as measured in healthcare 
expenditures, medications, and lost productivity due to disability. The incidence of 
metabolic disease (including the metabolic syndrome and type 2 diabetes) is also 
increasing at an alarming rate in parallel with associated risk factors (Ford et al 2004). 
This has led to an expansion in populations who are at increased risk of developing 
CVD at an earlier age.
Important advances in CVD and metabolic disease management have been facili-
tated by the identiﬁ  cation of a number of major risk factors, including hypertension, 
hyperlipidemia, insulin resistance, and obesity. Furthermore, studies determining the 
interrelated nature of risk factors have helped shape our approach to treatment. How-
ever, despite a large clinical evidence base, the implementation of strategies to prevent 
CVD and metabolic disease remain far from optimal. In this review data are presented 
underscoring the importance of an intensive global approach to risk management to 
reduce the clinical and economic burden, proﬁ  ling the most appropriate therapeutic 
interventions to achieve this.
Risk factors
Elevated blood pressure (BP), unfavorable levels of LDL and high density (HDL) 
cholesterol, cigarette smoking, obesity, physical inactivity, and diabetes are well 
established as major, modiﬁ  able CV risk factors (Hubert et al 1983). A critically Vascular Health and Risk Management 2007:3(6) 986
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important characteristic of risk factors is that each has a 
continuous, progressive impact on total CV risk, with higher 
levels translating into greater risk (Greenland et al 2003). 
Universal improvements in disease management and public 
health measures have led to an increasingly aging popula-
tion in whom these risk factors have more time to cause 
vascular disease.
CV risk factors occur in clusters
Rather than existing in isolation, CV risk factors tend to occur 
as clusters (Mancia 2006). For example, in a study determin-
ing the prevalence of CV disease risk factors among 14,690 
Chinese adults aged 35–74 years, overall, 80.5%, 45.9%, 
and 17.2% of individuals had 1, 2, and 3 modiﬁ  able 
CVD risk factors (from dyslipidemia, hypertension, diabetes, 
cigarette smoking, or being overweight), respectively. In the 
US, the ﬁ  gures were 93.1%, 73.0%, and 35.9%, respectively 
(Gu et al 2005). The metabolic syndrome is a particularly 
well-characterized example of co-existing CV and metabolic 
risk factors that is increasing in prevalence at an alarming rate 
(Elabbassi and Haddad 2005). Several international organiza-
tions have published guidelines for diagnosis of the metabolic 
syndrome, and differences between guidelines highlight 
the debate surrounding the precise nature of the metabolic 
syndrome. In 2006, the International Diabetes Federation 
(IDF) produced an updated consensus on the deﬁ  nition of 
the metabolic syndrome which includes central obesity and 
two additional metabolic criteria (Table 1).
As seen in Table 1, metabolic syndrome is a condition, 
characterized by obesity, in which an individual has a cluster 
of risk factors that can lead to CVD. The clustering of key 
risk factors in metabolic syndrome is considered by some 
to be the result of insulin resistance (Daskalopoulou et al 
2004); consequently, the syndrome also carries a greatly 
increased risk for the development of type 2 diabetes, which 
in turn increases CV risk even further (Zieve 2004). Typi-
cally, patients with metabolic syndrome will be older, obese, 
hypertensive (Csaszar et al 2006), and have insulin resistance 
(McLaughlin et al 2003; Grundy 2006). Global estimates 
of this condition are reported to be around 16% (Wild and 
Byrne 2005); although the situation in the United States is 
more advanced, where between 30%–40% of the popula-
tion are reported to have metabolic syndrome (Cheung et al 
2006; Ford 2005).
Clinical relevance of risk factor clustering
The relationship between CV risk factors is synergistic, 
meaning that when multiple risk factors are present in a 
speciﬁ  c individual, each one is more important than if they 
were present in isolation (Greenland et al 2003). Indeed, 
several studies have shown that a progressively greater 
number of additional CV risk factors is associated with a 
correspondingly poorer clinical outcome (Stamler et al 1993; 
Thomas et al 2001).
The cumulative effect of modiﬁ  able risk factors was 
well illustrated in the INTERHEART study (Figure 1) 
(Yusuf et al 2004). This standardized case-controlled 
study of acute myocardial infarction (MI) in 52 countries 
enrolled 15,152 cases and 14,820 controls. The relation-
ship of smoking, history of hypertension or diabetes, waist:
hip ratio, dietary patterns, physical activity, consumption 
of alcohol, blood apolipoproteins, and psychosocial fac-
tors to MI was demonstrated. The odds ratio (OR) for the 
association of these risk factors to MI and their respective 
population attributable risk (PAR) were calculated and 
the nine risk factors studied were reported to collectively 
represent more than 90% of the risk of an initial MI. In a 
similar analysis conducted by Baena Diez and colleagues 
(2002), the association between increasing numbers of 
CV risk factors and the risk of suffering a major CV event 
Table 1 The new International Diabetes Federation deﬁ  nition 
for the metabolic syndrome (IDF 2006) 
Central obesity (deﬁ  ned as waist circumference 94 cm for 
Europid men and 80 cm for Europid women, with ethnicity 
speciﬁ  c values for other groups)
And any two of the following four factors:  Level
Reduced HDL cholesterol  40 mg/dL (1.03 mmol/L)
  in males and 
  50 mg/dL (1.29 mmol/L)
  in females, or speciﬁ  c
  treatment for this lipid 
 abnormality.
Raised BP  systolic BP 130 or diast-
 olic  BP  85 mmHg, or 
  treatment of previously
 diagnosed  hypertension.
Raised triglyceride level  150 mg/dL (1.7 mmol/L),
 or  speciﬁ  c treatment 
  for this lipid abnormality.
Raised fasting plasma glucose  100 mg/dL (5.6 mmol/L), 
 or  previously 
  diagnosed type 2 diabetes. 
  If above 5.6 mmol/L or 
  100 mg/dL, oral glucose 
  tolerance test is strongly
  recommended but is 
  not necessary to deﬁ  ne
  presence of the 
 syndrome.Vascular Health and Risk Management 2007:3(6) 987
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was investigated in a study population of 2,248 patients. 
The results showed that the percentage of patients with 
1, 2, 3, and 4–6 CV risk factors (from smoking, arterial 
hypertension, hypercholesterolemia, hypertriglyceridemia, 
diabetes or obesity) was 32.8%, 17.5%, 6.9%, and 3.7%, 
respectively. The OR for experiencing a CV event associ-
ated to 1, 2, 3, and 4–6 CV risk factors was 1.6 (CI 95%: 
0.9–2.7), 2.8 (CI 95%: 1.7–4.7), 3.6 (CI 95%: 1.9–6.5), and 
5.6 (CI 95%: 2.9–10.8), respectively, again underlining the 
escalating risk associated with multiple risk factors.
The mortality associated with the presence of additional 
CV risk factors in subjects with or without hypertension 
was analyzed in a study involving 80,000 male subjects 
(Thomas et al 2001). The population was composed of 
29,640 normotensive men without additional risk factors 
(reference group) and 60,343 men with hypertension with and 
without additional risk factors (familial history of diabetes; 
total cholesterol 250 mg/dL; heart rate 80 beats/min; 
current smoker; and body mass index [BMI] 28 kg/m2). In 
patients aged 55 years with hypertension and one or two 
additional CV risk factors, CV mortality increased ﬁ  ve-fold 
in comparison with normotensive patients. The increased 
risk was even more apparent in patients who had more than 
two associated risk factors, where a 15-fold increase in CV 
risk was observed.
The clinical relevance of risk factor clustering is also well 
illustrated in patients with the metabolic syndrome. In a study 
of men aged between 42–60 years, the risk of CVD mortal-
ity over approximately 11 years increased at a considerably 
higher rate when they had metabolic syndrome (Figure 2) 
(Lakka et al 2002). Such patients are at considerable risk 
of developing atherosclerosis-related diseases, including 
a two- to four-fold increased risk of stroke and a three- to 
four-fold increased risk of MI compared with those without 
the metabolic syndrome (Lakka et al 2002; Ninomiya et al 
2004). The metabolic syndrome also increases the risk of 
developing diabetes ﬁ  ve- to nine-fold (Hanson et al 2002; 
Laaksonen et al 2002).
Implications for treatment
Screening for risk factors
The synergistic relationship between individual CV risk factors 
should make the identiﬁ  cation and characterization of clusters 
a healthcare priority. If a patient presents with a particular risk 
factor, such as elevated BP, they should receive appropriate 
antihypertensive treatment; however, to establish total risk, 
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Figure 1 Cumulative effects of modiﬁ  able risk factors in the INTERHEART study – risk of acute MI associated with exposure to multiple risk factors. Copyright © 2004. 
Reprinted with permission from Elsevier from Yusuf S, Hawken S, Ounpuu S, et al 2004. Effect of potentially modiﬁ  able risk factors associated with myocardial infarction in 
52 countries (the INTERHEART study): case-control study. Lancet, 362:937–52.Vascular Health and Risk Management 2007:3(6) 988
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a thorough patient assessment should be undertaken. Global risk 
assessment strategies have a number of beneﬁ  ts (Hackam and 
Anand 2003). A major beneﬁ  t is that they raise awareness that 
CV risk is continuous and graded, and that it is related to the 
overall burden of risk. They also facilitate adjustment to take 
into account the severity of individual component risk factors. 
Furthermore, they emphasize that a more individualized treat-
ment approach is required and reiterate that the clinician must 
not focus on one speciﬁ  c risk factor when multiple CV risk 
factors are present concomitantly (Hackam and Anand 2003). 
Widely used risk assessment tools include the Framingham risk 
charts and the Systematic Coronary Risk Evaluation (SCORE) 
risk predicting system. It should be recognized that risk assess-
ment tools should be used with a great amount of clinical 
judgment and the risk score should never be the only reason 
for treatment. Many factors that convey an increased risk are 
not included in the algorithms eg, abdominal obesity, low/high 
HDL, proteinuria, family history, exercise habits, food habits, 
and psychosocial factors. An individualized approach is there-
fore always needed to manage CV risk optimally.
The limitation of all risk scores is also that they only deﬁ  ne 
the CV risk over a limited period of time, usually 10 years. 
Furthermore, since global risk increases signiﬁ  cantly with 
age they underestimate the risk in young individuals over a 
life-long perspective. Consequently, in young subjects, even 
with a clustering of risk factors, the calculated global risk is 
not high enough to base treatment on a ‘high-risk’ concept. 
For those at a younger age it is probably easier for both the 
treating physician and the patient to visualize the risk as the 
‘relative risk increase’ rather than the total risk. However, the 
fact that global risk will escalate with age alone is one that 
should not be ignored. Clearly, the communication of risk 
and risk-factor management in younger individuals is still 
a problem and current algorithms are left distinctly lacking 
in this respect.
Figure 3 is based on the European Society of Cardiology 
(ESC) SCORE chart (Conroy et al 2003) and shows how age 
alone changes the 10-year risk if a patient with the same risk 
proﬁ  le is seen at different age brackets. It is also clear that 
young individuals are at lower risk even in the presence of 
signiﬁ  cant risk factors, and there is the potential for lowering 
risk if treatment is initiated earlier.
Multifactorial treatment approach to 
reduce CV events and the development 
of metabolic disease
Treatment guidelines and society recommendations for the 
management of CVD and metabolic disease recognize that a 
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Figure 2 Relative risk for cardiovascular disease mortality in men (aged 42 and 60 years at baseline) with and without metabolic syndrome. Copyright © 2002 American 
Medical Association. All rights reserved. Reprinted from Lakka HM, Laaksonen DE, Lakka TA, et al 2002. The metabolic syndrome and total and cardiovascular disease mor-
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multifactorial approach is required. For example, risk scoring 
and the subsequent implementation of treatment as appropri-
ate is central to the European Society of Hypertension–European 
Society of Cardiology (ESH–ESC) guidelines, which rec-
ommend stratifying patients according to prognosis based 
on BP levels, lifestyle, target organ damage, and diabetes 
(ESH–ESC Guidelines Committee 2003). The ESH–ESC 
guidelines recommend that treatment should address all of 
these factors and provide BP targets based on overall risk. For 
example, in patients with diabetes the recommended target 
BP is lower than that considered acceptable for the general 
population. Current Joint European Societies Cardiovascular 
Disease Prevention Guidelines and National Cholesterol 
Education Program Adult Treatment Panel III (NCEP ATP 
III) Guidelines also recognize the need for a multifactorial 
approach and recommend the use of the risk-assessment 
charts to tailor treatment to each patient’s risk proﬁ  le (NCEP 
Expert Panel 2002; De Backer et al 2003). Similarly, the IDF 
supports an aggressive, multifaceted treatment approach for 
individuals with metabolic syndrome (IDF 2006). However, 
worldwide, physicians still tend to focus on managing a single 
CV risk factor, for example BP, rather than focusing on over-
all risk management (Volpe and Tocci 2006). This situation 
must change if decreases in CV mortality and morbidity, and 
metabolic disease are to be achieved.
Over recent years, data have emerged to quantify the 
beneﬁ  ts of a global approach. The Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT) trial showed the beneﬁ  ts 
of combining antihypertensive and statin therapy (Sever 
et al 2003). The primary objective of each of the two arms 
of ASCOT (BP lowering arm and lipid-lowering arm [LLA]) 
was to assess the differential effects on risk of nonfatal MI 
and fatal coronary heart disease (CHD) of two different treat-
ment strategies assessed in a 2 × 2 factorial design. Following 
unblinding of the BP treatments in ASCOT-LLA, it was 
observed that the primary endpoint (nonfatal MI and fatal 
CHD) was signiﬁ  cantly reduced by 53% in the amlodipine/
atorvastatin group compared with amlodipine/placebo.
Similarly, in an analysis conducted by Athyros and 
colleagues (2005), the effect of a multi-targeted treatment 
approach on CVD risk reduction in nondiabetic patients 
with metabolic syndrome was assessed. The study was a 
12-month, randomized, open-label study, in which 300 
nondiabetic patients with the metabolic syndrome and free 
of CVD at baseline, received lifestyle advice and a stepwise-
implemented drug treatment for hypertension, impaired 
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Figure 3 Change in risk for cardiovascular disease deaths with increasing age (based on the European Society of Cardiology (ESC) SCORE chart) for a woman in a high-
risk population who smokes and has high cholesterol and high blood pressure, compared with a nonsmoker with lower cholesterol and blood pressure values. Data drawn 
from Conroy RM, Pyorala K, Fitzgerald AP, et al 2003. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J, 24:987–1003.Vascular Health and Risk Management 2007:3(6) 990
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fasting glucose and obesity. The patients were randomly 
allocated to three treatment groups for hypolipidemic 
treatment: atorvastatin (n = 100), micronized fenoﬁ  brate
(n = 100), and both drugs (n = 100). At study end, lipid values 
were signiﬁ  cantly improved in all three treatment groups, 
with those treated with both atorvastatin and micronized 
fenoﬁ  brate attaining lipid targets to a greater extent than 
those in the other two groups. The study ﬁ  ndings support 
the concept that a target-driven and intensiﬁ  ed intervention 
aimed at multiple risk factors in nondiabetic patients with 
the metabolic syndrome substantially offsets its component 
factors, and signiﬁ  cantly reduces the estimated CVD risk 
(Athyros et al 2005).
Individual risk factor management as part 
of a global approach
In order to prevent CV and metabolic diseases, each risk 
factor should be examined and treated appropriately within 
the context of a multifactorial approach (Table 2).
Lifestyle modiﬁ  cation
Guidelines for the management of CV and metabolic dis-
ease recognize the importance of lifestyle modiﬁ  cations 
for reducing CV risk. The Joint National Committee on 
Prevention, Detection, Evaluation and Treatment of High 
BP (JNC) VII guidelines recommend that treatment to meet 
BP targets should begin with lifestyle modiﬁ  cation, includ-
ing weight reduction, adoption of the Dietary Approaches to 
Stop Hypertension (DASH) eating plan, reduction of dietary 
sodium, regular aerobic physical activity and moderation 
of alcohol consumption (Table 2) (Chobanian et al 2003). 
The ESH-ESC and NCEP ATP III guidelines make similar 
recommendations (NCEP Expert Panel 2002; ESH–ESC 
Guidelines Committee 2003). Smoking cessation programs 
are also integral to management of overall CV risk (ESH–
ESC Guidelines Committee 2003), and provide one of the 
single most effective lifestyle changes that can be made to 
reduce the risk of non-CV and CV diseases (Table 2) (Doll 
et al 1994).
Obesity management
Obesity rates are increasing in epidemic proportions (Hed-
ley et al 2004). Abdominal obesity is particularly strongly 
associated with CV risk and has been shown to increase 
the risk of ischemic stroke by approximately three-fold 
(Suk et al 2003). As well as being a signiﬁ  cant independent 
risk factor for CV disease, obesity is associated with an 
increased risk of developing other conditions associated 
Table 2 Major intervention strategies and recommendations for 
the management of the individual risk factors associated with 
cardiovascular and metabolic disease
Intervention Recommendations
Lifestyle changes (Chobanian et al 2003,  
NCEP Expert Panel 2002; ESH-ESC  
Guidelines Committee 2003):
Weight reduction  Maintain BMI of
   18.5–24.9  kg/m2.
Adoption of DASH eating plan  Consume a diet rich
    in fruits, vegetables  
    and low-fat dairy pro-
    ducts with a reduced
    content of saturated
    and total fat.
Reduction of dietary sodium   100 mmol/day.
Regular aerobic activity  30 minutes per day,
    most days of the week.
Moderation of alcohol consumption   2 drinks* per day for
   men  ≤1 drink per day  
    for women and lighter-
   weight  individuals.
Smoking cessation  If necessary, nicotine
   replacement  or 
   bupropion  therapy
    should be considered.
Obesity management   Primarily through life-
    style changes but anti-
    obesity drugs (eg, 
   sibutramine,  orlistat
    and topiramite) may 
    be used if required.
    (Klein 2004; Li et al
   2005).
Insulin resistance management   Lifestyle modiﬁ  cations
    are recommended as 
   ﬁ  rst-line therapy
   (Daskalopoulou  2004;
    Zieve 2004; Wagh and
    Stone 2004; Grundy
    2005;  Vitale 2006),
    however, if this does
    not stop blood glucose
    levels rising towards
    diabetic levels and
    clustering of risk
    factor progresses, inter- 
    vention with drugs is  
   essential  (Grundy
   2006).
BP lowering   BP should be
   140/90 mmHg in
   individuals 
 with  hypertension
  and no other risk
 factors  or  130/
  80 mmHg in patients
  with diabetes or
  chronic kidney disease
  (continued)Vascular Health and Risk Management 2007:3(6) 991
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with CV risk. Furthermore, in obese individuals there is 
a high likelihood that they will have insulin resistance 
(McLaughlin et al 2004), which puts them at an increased 
risk from type 2 diabetes (Grundy 2005). The central role of 
obesity in the metabolic syndrome has been highlighted by 
the recent IDF deﬁ  nition for the metabolic syndrome (Table 
1), which stipulates that for an individual to be diagnosed 
with the syndrome they must have central obesity, deﬁ  ned 
as waist circumference 94 cm for Europid men and 80 
cm for Europid women, with ethnicity-speciﬁ  c values for 
other groups (IDF 2006). Furthermore, a study of 22,171 
men in the Health Professionals Follow-up Study showed 
that for every kilogram of weight gained, there was a 7.3% 
increase in the risk of developing diabetes (Koh-Banerjee 
et al 2004). In this study, 56% of cases of diabetes were 
attributed to weight gain greater than 7 kg and 20% were 
attributed to a waist gain exceeding 2.5 cm. Whilst lifestyle 
modiﬁ  cation remains the major approach to the management 
of obesity, a number of anti-obesity drugs are available or 
in development and may have a role in reducing CV risk 
in obese or overweight patients (Table 2) (Klein 2004). 
A meta-analysis of clinical trials showed that sibutramine, 
orlistat and topiramate all reduced bodyweight in obese 
patients, while sibutramine was also associated with small 
improvements in HDL cholesterol (HDL-C) and very small 
improvements in glycemic control in patients with diabetes 
(Table 2) (Li et al 2005).
As suggested for obesity, it is advocated that insulin 
resistance, as another underlying factor in the develop-
ment of metabolic syndrome, is treated with lifestyle 
modiﬁ  cation as ﬁ  rst-line therapy in order to prevent the 
development of type 2 diabetes and reduce the risk of CV 
disease (Daskalopoulou 2004; Zieve 2004; Wagh and 
Stone 2004; Grundy 2005; Vitale 2006). However, when 
lifestyle modiﬁ  cation is no longer able to arrest the rise 
in blood glucose towards diabetic levels and clustering of 
risk factors progresses, intervention with drugs directed 
towards the individual risk factors is essential (Table 2) 
(Grundy 2006).
BP lowering
Antihypertensive therapy to reduce BP is central to the 
management of CV risk and provides a starting point for ini-
tiating a more comprehensive CV risk management strategy 
(Chobanian 2003; El-Atat et al 2006; Epstein 2006; Sowers 
2006). The Joint European Societies Cardiovascular Disease 
Prevention guidelines specify BP targets of 140/90 mmHg 
for individuals with hypertension and no other risk factors 
and 130/80 mmHg for patients with diabetes or chronic 
kidney disease (Table 2) (De Backer et al 2003; Erhardt and 
Gotto 2006). However, there is increasing evidence that even 
more aggressive BP targets may be warranted for patients at 
increased CV risk.
In a recent prospective cohort analysis among 8,960 
middle-aged adults in the Atherosclerosis Risk in Communi-
ties (ARIC) study, individuals with prehypertensive levels 
of BP were found to have an increased risk of developing 
CVD relative to those with optimal levels (Kshirsagar et al 
2006). The association was found to be more pronounced 
among blacks, individuals with diabetes mellitus, and those 
with high BMI.
The ability to stratify patients according to their calculated 
total CV risk also questions whether high-risk patients, not 
classiﬁ  ed as hypertensive, should also receive antihyperten-
sive therapy (Mancia 2006). For example, a number of stud-
ies have shown that intensive BP lowering, even in patients 
whose baseline BP is 140/90 mmHg, is beneﬁ  cial in high-
risk patients, including those with diabetes (Yusuf et al 2000; 
PROGRESS Collaboration Group 2001; Schrier et al 2002). 
Table 2 (Continued)
Intervention Recommendations
    (De Backer et al 2003;
    Erhardt and Gotto 2006).
Dyslipidemia management  All patients aged 80 years
    with active coronary
    heart disease, peri-
    pheral arterial disease,
    history of ischemia, 
    stroke or long-standing
    type 2 diabetes should
    receive a statin if their
    total cholesterol is
   3.5 mmol/L. Patients
    without CV disease or
    recent on-set diabetes
   whose  estimated
    10 year CV risk 20%
    should also receive a
    stain if their total chol
   esterol  is  3.5 mmol/L
   (ESH-ESC  Guidelines
   Committee  2003).
New-onset diabetes prevention  Treatment with oral
    antidiabetic agents and 
   potentially  ACE-Is  or
    ARBs (McCall et al 2006).
Abbreviations: BMI, body mass index; ACE-Is, angiotensin converting enzyme 
inhibitors; ARBs, angiotensin II receptor blockers; CV, cardiovascular. 
Notes: *deﬁ  ned as 1 oz or 30 mL ethanol eg, 24 oz of beer, 10 oz wine or 3 oz 
of 80-proof whiskey.Vascular Health and Risk Management 2007:3(6) 992
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Although guideline BP target recommendations have become 
more aggressive in recent years, these results combined 
with other existing data question whether current recom-
mendations go far enough. Indeed, The Writing Group of the 
American Society of Hypertension (Giles et al 2005) recently 
proposed a redeﬁ  nition of hypertension away from arbitrary 
thresholds and towards overall CV risk status. Several of 
the current guidelines already recognize that patients with 
hypertension plus a cluster of risk factors require a total CV 
risk management strategy (ESH–ESC Guidelines Committee 
2003; Chobanian 2003; De Backer et al 2003; Whitworth et al 
2003; Williams et al 2004; BCS et al 2005; CHS 2005). As 
further evidence accumulates, this may prompt a revision to 
guideline targets.
Dyslipidemia management
Several large, randomized, controlled trials have documented 
that cholesterol-lowering therapy with statins reduces the 
risk of death or CV events across a wide range of cholesterol 
levels, and that lipid management is integral to reducing CVD 
risk. In common with BP targets, lipid-lowering goals are also 
becoming more stringent. A recent analysis of the evolution 
of the Joint European Societies’ guidelines with respect to 
their lipid recommendations stresses the importance of lower-
ing lipid levels to, or below, the currently recommended goals 
(Table 2) (Erhardt 2006). It was argued that the patients’ 
global risk for CVD, rather than baseline lipid levels, should 
direct the intensity of lipid-lowering treatment.
There is evidence that more stringent targets than those 
currently recommended by international guidelines may result 
in greater reductions in CV risk. In the Heart Protection Study 
(HPS) – a landmark trial that looked at the effect of ﬁ  xed-dose 
statin (simvastatin 40 mg/day) by low-density lipoprotein 
cholesterol LDL-C subgroups (LDL-C 135; 116–135; and 
116) – signiﬁ  cant LDL-C reductions were observed in each 
predeﬁ  ned LDL-C subgroup (LDL-C 135: 39%; LDL-C 
116–135: 37%; and LDL-C 116: 35%) and these reductions 
correlated to comparable relative risk reductions (major vascu-
lar events: 19%, 26%, and 21%, respectively), irrespective of 
baseline LDL-C levels (Brown 2002). Results from Pravastatin 
or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) 
in patients with acute coronary syndrome (Wiviott et al 2006) 
and Treating to New Targets (TNT) (LaRosa et al 2005) in 
patients with stable coronary artery disease, both showed that 
patients treated intensively to below target LDL levels experi-
enced clinically signiﬁ  cant beneﬁ  ts in CV outcomes.
Additionally, the recently published results from A Study 
to Evaluate the Effect of Rosuvastatin on Intravascular 
Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) 
showed that intensive treatment with rosuvastatin resulted in 
a 53% reduction in LDL-C (from 130 mg/dL to 60.8 mg/dL) 
at 24 months and this was associated with signiﬁ  cant regres-
sion of atherosclerosis, supporting the beneﬁ  ts of intensive 
lipid lowering (Nissen et al 2006).
Prevention of new-onset diabetes
Oral antidiabetic agents may provide a means to treat 
impaired glucose tolerance (IGT) and delay new-onset 
diabetes in patients with or without the metabolic syndrome 
(Table 2). In the Diabetes Prevention Program (DPP), treat-
ment with metformin reduced the risk of developing type 2 
diabetes by 31%, compared with placebo, in patients with 
prediabetes (Kitabchi et al 2005). However, this reduction 
was smaller than that achieved with intensive lifestyle 
modification (58%). Recent thiazolidinedione studies 
have also demonstrated efﬁ  cacy in delaying or preventing 
type 2 diabetes in patients with IGT and insulin resistance 
(Buchanan et al 2002; Knowler et al 2002). Other studies 
have shown that both acarbose and orlistat can be used to 
delay the development of type 2 diabetes in patients with IGT 
(Chiasson et al 2003; Torgerson et al 2004). In addition, the 
Diabetes REduction Assessment with rAmipril and rosigli-
tazone Medication (DREAM) (ramipril and rosiglitazone) 
study which enrolled 5,269 adults with impaired fasting 
glucose (IFG) or IGT, showed that rosiglitazone reduced 
the risk of new type 2 diabetes by 60% (DREAM Trial 
Investigators 2006a). In contrast, although ramipril resulted 
in a signiﬁ  cant number of patients achieving normoglycemia 
(p = 0.001 vs placebo), it did not signiﬁ  cantly reduce the risk 
of developing type 2 diabetes (DREAM Trial Investigators 
2006b).
In addition to the beneﬁ  ts of BP reduction per se, there 
is strong evidence that angiotensin converting enzyme 
inhibitors (ACE-Is) and angiotensin II receptor blockers 
(ARBs) are associated with a reduction in the risk of new-
onset diabetes (Table 2) (McCall et al 2006). However, 
recent data from the DREAM study showed that although 
the ACE-I ramipril modestly improved glycemic status in 
patients with IFG or IGT; it had no signiﬁ  cant effect on the 
risk of new type 2 diabetes (DREAM Trial Investigators 
2006b). More favorable results have been reported from 
studies of ARBs such as the Valsartan Antihypertensive 
Long-term Use Evaluation (VALUE) study, in which the 
ARB valsartan was found to reduce the risk of new-onset 
diabetes by 23% compared with the calcium channel blocker 
amlodipine in patients with hypertension and at high risk of Vascular Health and Risk Management 2007:3(6) 993
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cardiac events (Julius et al 2004). Similarly, in the Losartan 
Intervention For Endpoint reduction in hypertension (LIFE) 
study, patients with hypertension and left ventricular hyper-
trophy who received the ARB losartan had a 25% reduction 
in new-onset diabetes compared with patients receiving 
the β-blocker atenolol (Dahlöf et al 2002). Candesartan 
was also found to reduce the risk of new-onset diabetes by 
25% in elderly patients with hypertension in the Study on 
Cognition and Prognosis in the Elderly (SCOPE) (Lithell 
et al 2003) and by 40% in patients with congestive heart 
failure in the Candesartan in Heart Failure Assessment of 
Reduction in Mortality and morbidity (CHARM)-preserved 
study (Yusuf et al 2003). In addition, the Antihypertensive 
treatment and Lipid Proﬁ  le In a North of Sweden Efﬁ  cacy 
Evaluation (ALPINE) study showed that candesartan was 
associated with new diagnoses of type 2 diabetes in only one 
of 197 patients, compared with eight of 196 patients receiving 
hydrochlorothiazide (Lindholm et al 2003).
Currently, there is little or no evidence that preventing 
diabetes will translate into subsequent prevention of CV 
events. As such, it remains unproven that patients would 
beneﬁ  t from diabetes prevention in terms of reductions 
in CV events. The ongoing Nateglinide And Valsartan in 
Impaired Glucose Tolerance Outcomes Research (NAVI-
GATOR) trial in patients with IGT and CVD or at CV risk, 
the largest diabetes trial with an ARB conducted to date, is 
the only diabetes prevention study also powered to show a 
reduction in CVD and will provide important information 
on this topic.
Management issues
Awareness and detection of risk factors
Effective management of CV risk and metabolic disease 
through intensive treatment of multiple risk factors must 
overcome several key obstacles. Firstly, the risk factors need 
to be detected earlier and quantiﬁ  ed. Rates of detection and 
treatment of CV risk factors are low. For example, as part of 
the Multinational MONItoring of trends and determinants in 
CArdiovascular disease (MONICA) study, it was found that 
in Northern Sweden, only 50% of individuals with hyperten-
sion received treatment and the majority of these patients 
were uncontrolled(Jansson et al 2003). Europe-wide data 
from MONICA showed that awareness of hypercholesterol-
emia varied considerably between populations, with 3%–62% 
of men and 0%–65% of women being aware of their elevated 
cholesterol (Tolonen et al 2005). Low levels of awareness 
result in low levels of treatment: in the MONICA study only 
45% of men and 44% of women were receiving treatment for 
their hypercholesterolemia. Public health education plays an 
integral part in raising awareness about CV risk factors.
Improved screening for CV risk factors and the metabolic 
syndrome is vital if long-term reductions in overall morbidity 
and mortality are to be achieved. Many CV risk factors (such 
as hypertension, hypercholesterolemia, or IGT) are ‘silent’ 
and individuals will not necessarily be aware that they are at 
an increased risk. Reducing overall CV risk therefore needs to 
begin by evaluating all known modiﬁ  able risk factors so that 
a detailed CV and metabolic risk-status proﬁ  le can be created 
and appropriate management implemented. Secondly, while 
many individuals recognize that their behavior is associated 
with increased CV risk, there is often a lack of motivation 
to make lifestyle changes. Strategies such as motivational 
interviewing (Shinitzky and Kub 2001) and improving com-
munity opportunities for physical activity can be effective at 
helping patients to implement and maintain lifestyle changes. 
Thirdly, physicians need to recognize the importance of early 
and aggressive treatment and make appropriate therapeutic 
interventions based on current guidelines and accurate risk 
assessment. However, physicians’ assessments of CV risk 
may deviate signiﬁ  cantly from scores measured using the 
risk charts, suggesting that initiatives are needed to promote 
accurate risk assessment techniques (Mosca et al 2005). 
Generally, primary care physicians seem to underestimate 
total CV risk (Figure 4), thus making the use of tools to 
assess the CV risk important in clinical practice (Backlund 
et al 2004).
Future algorithms need to be able to assess lifetime risk 
and guide the clinician toward optimal treatment, even if, 
as in younger individuals, the 10-year risk of CV events is 
not excessively high.
Compliance and persistence
Once pharmacological interventions have been prescribed, 
patients need to exhibit a high level of compliance and per-
sistence in order to derive optimal beneﬁ  t from the therapy. It 
has been estimated that poor therapeutic compliance contrib-
utes to lack of BP control in over two-thirds of patients with 
hypertension, while up to half of patients receiving antihyper-
tensive drugs discontinue treatment within 6 months to 4 years 
(Anonymous 2005). This lack of compliance can invariably 
lead to increased resource utilization, which in turn, will lead 
to increased economic burden (Figure 5) (Goldman et al 2006). 
Improved compliance to medication signiﬁ  cantly reduces this 
burden. Prescription patterns among primary care physicians 
have been shown to inﬂ  uence discontinuation of medication 
and general practitioners with high levels of prescribing attain Vascular Health and Risk Management 2007:3(6) 994
Erhardt
Framingham calculated risk
Perceived risk
R
i
s
k
 
(
%
)
0
10
20
30
33
10 10
14
5
27
40
50
60
Man 61 years Women 66 years Women 51 years
Smoker Smoker Diabetic
LDL cholesterol LDL cholesterol LDL cholesterol
Total cholesterol Total cholesterol Total cholesterol
6.3 mmol/L 4.6 mmol/L 4.3 mmol/L
6.5 mmol/L 8.2 mmol/L
178 mg/dL 166 mg/dL
255 mg/dL
6.9 mmol/L
317 mg/dL 267 mg/dL
244 mg/dL
Figure 4 Comparison of actual versus perceived 10-year risk among 80 Swedish general practitioners when asked to estimate the risk of speciﬁ  c patient proﬁ  les. Data drawn 
from Backlund L, Bring J, Strender L-E. 2004. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients? Primary Health 
Care Research and Development, 5:145–52.
All-cause All-cause CV CV
0
200
400
600
800
1000
Hospitalization
Fully compliant
Partially complaint/Non complaint
p < 0.01
Emergency department visit
A
d
j
u
s
t
e
d
 
u
t
i
l
i
z
a
t
i
o
n
 
r
a
t
e
s
 
a
m
o
n
g
 
p
a
t
i
e
n
t
s
 
a
t
 
h
i
g
h
 
r
i
s
k
 
f
o
r
 
C
H
D
 
(
p
e
r
 
1
0
0
0
 
p
a
t
i
e
n
t
s
)
Figure 5 Emergency resource utilization in fully compliant and partial/non compliant patients with high risk for coronary heart disease. Data drawn from Goldman DP, 
Joyce GF, Karaca-Mandic P. 2006. Varying pharmacy beneﬁ  ts with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care, 12:21–8.Vascular Health and Risk Management 2007:3(6) 995
Multiple risk factor intervention
higher rates of early discontinuation compared with colleagues 
with low levels of prescribing (Hansen at al 2007). Strategies 
that have been shown to improve compliance and persistence 
include the use of drugs with convenient dosing regimens 
and better tolerability proﬁ  les, however, the importance of 
adherence still needs to be reinforced by governmental and 
health agencies.
Conclusions
Cardiovascular disease and metabolic disease are character-
ized by multiple concurrent and interrelated causes. Many 
risk factors for CVD can be treated effectively with existing, 
well-tolerated pharmacotherapies. There is now convincing 
evidence of the need for an early, intensive, and integrated 
approach to the management of multiple risk factors for 
CV disease to reduce the long-term clinical burden. Risk-
factor screening, recognition of risk factor clustering and an 
integrated approach to multiple risk management, together 
with government and health agency driven public education, 
should result in reductions in total CV and metabolic risk, 
with concurrent clinical and economic beneﬁ  ts.
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